Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in children and adolescents with relapsing-remitting multiple sclerosis
2023-507313-94-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) (2 cohorts), sponsored by Roche. Primary endpoints: Serum concentration of ocrelizumab at specified timepoints and Levels of CD19+ B-cell count in blood. Planned start Dec 2023; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2023-507313-94-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507313-94-00.